Poietis worked with pharmaceutical company Servier to develop a 4D bioprinted liver model that can better predict the liver toxicity of drugs.
Hepatotoxicity testing is one of the key tests conducted during preclinical trials using study drugs. Bruno Brisson, co-founder of Poietis, said, “The role of the liver is to degrade substances that are toxic to the body into non-toxic products, but sometimes excessive toxicity can cause important liver lesions.” Animal models of human hepatocytes and cell culture are usually used To predict toxicity, but because they cannot fully replicate the processes that occur in the liver of a real human, their accuracy is limited.
Using Poietis’ bioprinting technology, you can better perform tests to predict liver toxicity. Using the company’s laser-assisted bioprinting technology, the liver model contains different types of human liver cells and immune cells, which can be distributed in three dimensions with high precision. Brisson further explained, “Most of the in vitro liver models used for drug analysis are generated using two-dimensional monolayer cell tissue, but this new three-dimensional model better simulates the complex liver multicellular tissue structure. Drug toxicity testing is of great significance. The model will be validated by testing a group of compounds that can or cannot induce liver toxicity. Brisson is expected to complete it within 18 months.
